[ad_1]
CHENGDU, China, Nov. 13, 2022 /PRNewswire/ — Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE:688222.SH) today announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd (“Daewoong”), a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients’ lives. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small , drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
Full story available on Benzinga.com
[ad_2]
Source link
